Advertisement

Annals of Surgical Oncology

, Volume 20, Issue 6, pp 1941–1948 | Cite as

Association of Depression and Anxiety on Quality of Life, Treatment Adherence, and Prognosis in Patients with Advanced Non-small Cell Lung Cancer

  • Óscar ArrietaEmail author
  • Laura P. Angulo
  • Carolina Núñez-Valencia
  • Yuzmiren Dorantes-Gallareta
  • Eleazar O. Macedo
  • Dulce Martínez-López
  • Salvador Alvarado
  • José-Francisco Corona-Cruz
  • Luis F. Oñate-Ocaña
Thoracic Oncology

Abstract

Background

Symptoms of depression and anxiety are common in patients with lung cancer and may produce an impact on both health-related quality of life (HRQL) and survival. The aim of the present study was to evaluate the association of depression and anxiety on HRQL, treatment adherence, and prognosis in patients with non-small cell lung cancer (NSCLC).

Methods

This is a prospective study of patients with stage IIIB or IV NSCLC. Depression and anxiety were measured using the hospital anxiety and depression scale, the International Neuropsychiatric Interview, and the HRQL with the EORTC QLQ-C30 and QLQ-LC13 questionnaires. Instruments were applied before treatment and repeated at 3 and 6 months. Lack of treatment adherence was considered as patients who stopped going to their consultation appointments.

Results

A total of 82 patients were included. At the initial evaluation, depression and anxiety were found in 32.9 and 34.1 % of patients, respectively. Depression was associated with feminine gender (p = 0.034) and poor performance status (p = 0.048). Depression and anxiety showed an association with HRQL. Patients with depression showed median overall survival of 6.8 months, whereas that for nondepressed patients was 14 months (hazard ratio [HR], 1.9; 95 % confidence interval (95 % CI), 1.03–3.7; p = 0.042). The 58 % of patients with depression had poor treatment adherence versus 42 % of patients without depression (p = 0.004).

Conclusions

Depression and anxiety were present in one-third of patients with recently diagnosed NSCLC. Depression and anxiety were associated with decreased HRQL scales, and depression was independently associated with treatment adherence and with poor prognosis.

Keywords

Depression Overall Survival Treatment Adherence Advanced NSCLC Karnofsky Performance Status 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

This project was supported partially by Instituto Nacional de Cancerología (INCan) and CONACYT (115574).

Conflict of interest

The authors have nothing to disclose.

References

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr. Accessed 15 April 2012.
  2. 2.
    Medina-Morales F, Salazar-Flores M. Frecuencia y patrón cambiante del cáncer pulmonar en México. Salud Publica Mex. 2000;42:333–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Lazcano-Ponce EC, Tovar-Guzmán V, Meneses-González F, Rascon Pacheco RA, Hernandez Avila M. Trends of lung cancer mortality in Mexico. Arch Med Res. 1997;28:565–70.PubMedGoogle Scholar
  4. 4.
    D’Addario G, Felip E, ESMO Guidelines Working Group. Non-small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19:39–40.Google Scholar
  5. 5.
    Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995;311:899–909.CrossRefGoogle Scholar
  6. 6.
    NSCLC Meta-analysis Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617–25.CrossRefGoogle Scholar
  7. 7.
    Haura EB. Treatment of advanced non-small-cell lung cancer: a review of current randomized clinical trials and an examination of emerging therapies. Cancer Control. 2001;8:326–36.PubMedGoogle Scholar
  8. 8.
    Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542–50.PubMedCrossRefGoogle Scholar
  10. 10.
    Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet. 2009;373:1525–31.PubMedCrossRefGoogle Scholar
  11. 11.
    Pirl WF. Depresión, ansiedad y fatiga. In: Chabner BA, Lynch TJ, Longo DL, editors. Harrisons Manual de Oncología. Mexico City: McGraw-Hill de Mexico; 2011. p. 190–6.Google Scholar
  12. 12.
    Brintzenhofe-Szoc KM, Levin TT, Li Y, Kissane DW, Zabora JR. Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. Psychosomatics. 2009;50:383–91.PubMedCrossRefGoogle Scholar
  13. 13.
    Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Barton R, English A, Nabb S, Rigby AS, Johnson MJ. Randomised trial of high vs low intensity training in breathing techniques for breathless patients with malignant lung disease: a feasibility study. Lung Cancer. 2010;70:313–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Bredin M, Corner J, Krishnasamy M, Plant H, Bailey C, A’Hern R. Multicentre randomised controlled trial of nursing intervention for breathlessness in patients with lung cancer. BMJ. 1999;318:901–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Skaug K, Eide GE, Gulsvik A. Prevalence and predictors of symptoms in the terminal stage of lung cancer: a community study. Chest. 2007;131:389–94.PubMedCrossRefGoogle Scholar
  17. 17.
    Fayers PM, Machin D. Quality of life: assessment, analysis and interpretation. 2nd ed. New York: Wiley; 2007.Google Scholar
  18. 18.
    Carlsen K, Jensen AB, Jaconsen E, Krasnik M, Johansen C. Psychosocial aspects of lung cancer. Lung Cancer. 2005;47:293–4.PubMedCrossRefGoogle Scholar
  19. 19.
    Pirl WF, Temel JS, Billings A, Dahlin C, Jackson V, Prigerson HG, et al. Depression after diagnosis of advanced non-small cell lung cancer and survival: a pilot study. Psychosomatics. 2008;49:218–24.PubMedCrossRefGoogle Scholar
  20. 20.
    Nakaya N, Saito-Nakaya K, Akechi T, Kuriyama S, Inagaki M, Kikuchi N, et al. Negative psychological aspects and survival in lung cancer patients. Psychooncology. 2008;17:466–73.PubMedCrossRefGoogle Scholar
  21. 21.
    Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67:361–70.PubMedCrossRefGoogle Scholar
  22. 22.
    López-Alvarenga JC, Vázquez-Velázquez V, Arcila-Martínez D, Sierra-Ovando AE, González-Barranco J, Salín-Pascual RJ. Exactitud y utilidad diagnóstica del Hospital Anxiety and Depression Scale (HAD) en una muestra de sujetos obesos mexicanos [Accuracy and diagnostic utility of the Hospital Anxiety and Depression Scale (HAD) in a sample of obese Mexican patients]. Rev Invest Clin. 2002;54:403–9.PubMedGoogle Scholar
  23. 23.
    Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22–33.PubMedGoogle Scholar
  24. 24.
    Arrieta O, Núñez-Valencia C, Reynoso-Erazo L, Alvarado S, Flores-Estrada D, Angulo LP, et al. Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. Lung Cancer. 2012;77:205–11.PubMedCrossRefGoogle Scholar
  25. 25.
    Bergman B, Aaronson NK, Ahmezdai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer. 1994; 30:635–42.CrossRefGoogle Scholar
  26. 26.
    Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organisation for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:356–76.CrossRefGoogle Scholar
  27. 27.
    Arrarás JI, Pruja E, Marcos M, Tejedor M, Illarramendi JJ, Vera R, et al. El cuestionario de calidad de vida para cáncer de pulmón de la EORTC QLQ-LC13. Estudio de validación para nuestro país. Oncologia. 2000;23:127–34.Google Scholar
  28. 28.
    Greene FL, Balch CM, Fleming ID, Fritz AG, Haller DG, Morrow M, et al. (eds). AJCC cancer staging handbook from the AJCC cancer staging manual. 6th ed. New York: Springer; 2002.Google Scholar
  29. 29.
    Néron S, Correa JA, Dajczman E, Kasymjanova G, Kreisman H, Small D. Screening for depressive symptoms in patients with unresectable lung cancer. Support Care Cancer. 2007;15:1207–12.PubMedCrossRefGoogle Scholar
  30. 30.
    Rolke HB, Bakke PS, Gallefoss F. HRQoL changes, mood disorders and satisfaction after treatment in an unselected population of patients with lung cancer. Clin Respir J. 2010;4:168–75.PubMedCrossRefGoogle Scholar
  31. 31.
    Salvo N, Zeng L, Zhang L, Leung M, Khan L, Presutti R, et al. Frequency of reporting and predictive factors for anxiety and depression in patients with advanced cancer. Clin Oncol (R Coll Radiol). 2012;24:139–48.CrossRefGoogle Scholar
  32. 32.
    Sarna L. Effectiveness of structured nursing assessment of symptom distress in advanced lung cancer. Oncol Nurs Forum. 1998;25:1041–8.PubMedGoogle Scholar
  33. 33.
    Whitney KA, Steiner AR, Lysaker PH, Estes DD, Hanna NH. Dimensional versus categorical use of the PHQ-9 Depression Scale among persons with non-small-cell lung cancer: a pilot study including quality-of-life comparisons. J Support Oncol. 2010;8:219–26.PubMedCrossRefGoogle Scholar
  34. 34.
    Akechi T, Okamura H, Okuyama T, Furukawa TA, Nishiwaki Y, Uchitomi Y. Psychosocial factors and survival after diagnosis of inoperable non-small cell lung cancer. Psychooncology. 2009;18:23–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Chen ML, Chen MC, Yu CT. Depressive symptoms during the first chemotherapy cycle predict mortality in patients with advanced non-small cell lung cancer. Support Care Cancer. 2011;19:1705–11.PubMedCrossRefGoogle Scholar
  36. 36.
    Pirl WF, Greer JA, Traeger L, Jackson V, Lennes IT, Gallagher ER, et al. Depression and survival in metastatic non-small-cell lung cancer: effects of early palliative care. J Clin Oncol. 2012;20:1310–5.CrossRefGoogle Scholar
  37. 37.
    Mazzoccoli G, Carughi S, De Cata A, La Viola M, Giuliani A, Tarquini R, et al. Neuroendocrine alterations in lung cancer patients. Neuro Endocrinol Lett. 2003;24:77–82.PubMedGoogle Scholar
  38. 38.
    Mazzoccoli G, Vendemiale G, De Cata A, Carughi S, Tarquini R. Altered time structure of neuro-endocrine-immune system function in lung cancer patients. BMC Cancer 2010;10:314.PubMedCrossRefGoogle Scholar
  39. 39.
    Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008;8:887–99.PubMedCrossRefGoogle Scholar
  40. 40.
    Reiche EMV, Nunes SOV, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol. 2004;5:617–25.PubMedCrossRefGoogle Scholar
  41. 41.
    Illman J, Corringham R, Robinson D Jr, Davis HM, Rossi JF, Cella D, et al. Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol. 2005;3:37–50.PubMedGoogle Scholar
  42. 42.
    Padilla GV. Psychological aspects of nutrition and cancer. Surg Clin North Am. 1986;66:1121–35.PubMedGoogle Scholar
  43. 43.
    Tisdale MJ. Mechanisms of cancer cachexia. Physiol Rev. 2009;89:381–410.PubMedCrossRefGoogle Scholar
  44. 44.
    Sanchez K, Turcott J, Juarez E, Villanueva G, Dorantes Y, Garralda M, et al. Nutritional parameters improve survival of patients with advanced non-small cell lung cancer during chemotherapy treatment. J Thorac Oncol. 2011;6:S1301–2.CrossRefGoogle Scholar
  45. 45.
    Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet. 2000;356:1326–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Satin JR, Linden WL, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients. Cancer. 2009;115:5349–61.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2012

Authors and Affiliations

  • Óscar Arrieta
    • 1
    • 2
    Email author
  • Laura P. Angulo
    • 1
    • 3
  • Carolina Núñez-Valencia
    • 1
    • 4
  • Yuzmiren Dorantes-Gallareta
    • 1
  • Eleazar O. Macedo
    • 1
  • Dulce Martínez-López
    • 3
  • Salvador Alvarado
    • 4
  • José-Francisco Corona-Cruz
    • 5
  • Luis F. Oñate-Ocaña
    • 6
  1. 1.Thoracic Oncology ClinicInstituto Nacional de Cancerología (INCan)Mexico CityMexico
  2. 2.Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM)Mexico CityMexico
  3. 3.Psychiatry DepartmentInstituto Nacional de Cancerología (INCan)Mexico CityMexico
  4. 4.Psycho-Oncology DepartmentInstituto Nacional de Cancerología (INCan)Mexico CityMexico
  5. 5.Thoracic Surgery DepartmentInstituto Nacional de Cancerología (INCan)Mexico CityMexico
  6. 6.Clinical Research DivisionInstituto Nacional de Cancerología (INCan)Mexico CityMexico

Personalised recommendations